Unlocking the Potential of ARID4A as a Drug Target and Biomarker

Target Name: ARID4A

NCBI ID: G5926

ARID4A

Unlocking the Potential of ARID4A as a Drug Target and Biomarker

Introduction

ARID4A, a non-coding RNA molecule located in the nucleus, has been identified as a potential drug target and biomarker for various diseases. Its unique structure, composed of a domain that consists of 4 RNA-binding proteins (RBP1-3), has led to a high degree of interactivity with various protein partners, making it an attractive target for researchers to explore. In this article, we will delve into the ARID4A molecule, its potential drug targets, and its role as a biomarker in disease diagnosis and treatment.

Structure and Function

The ARID4A molecule is approximately 290 nucleotides in length and has a unique topology, with the 5' end containing a poly(A) tail and the 3' end featuring a higher-order RNA-binding domain (HOB) and a unique structure composed of 4 RBP1-RBP2-RBP3 domains. The RBP1 and RBP2 domains contain a characteristic Rossmann-fold, which is a common structural motif found in RNA-binding proteins, allowing them to form a strong interaction with various protein partners. The RBP3 domain, on the other hand, contains a unique feature called the N-terminal hypervariable region (N-VHR), which has been implicated in various cellular processes, including cell signaling, DNA replication, and protein-protein interactions.

ARID4A has been shown to play a critical role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. Its expression has been detected in various tissues and has been associated with various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

Potential Drug Targets

ARID4A has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. Several studies have shown that ARID4A interacts with various proteins, including histone modification enzymes, non-coding RNA-binding proteins (ncRNAs), and signaling proteins. Its interaction with these proteins suggests that ARID4A may play a role in modulating protein-protein interactions, influencing cellular processes, and contributing to the development of various diseases.

One of the most promising potential drug targets for ARID4A is the protein p16INK4a. p16INK4a is a key regulator of the cell cycle and has been implicated in various diseases, including cancer. It has been shown to interact with ARID4A and has been proposed as a potential drug target for ARID4A-mediated diseases.

In addition to p16INK4a, several other proteins have also been shown to interact with ARID4A. One of these proteins is the neurotransmitter GABA, which is known to modulate various cellular processes, including neurotransmission and synaptic plasticity. The interaction between ARID4A and GABA has been shown to play a role in modulating GABA-dependent signaling pathways and may contribute to the development of psychiatric disorders.

Biomarker Potential

The ARID4A molecule has also been identified as a potential biomarker for various diseases. Its unique structure and interactions with various proteins make it an attractive target for diagnostic tests and therapeutic interventions.

One of the most promising applications of ARID4A as a biomarker is its potential to serve as a diagnostic marker for cancer. Its interaction with the protein p16INK4a has been shown to be altered in various cancer types, making it a potential target for cancer diagnostics and therapies.

In addition to its potential as a diagnostic marker, ARID4A has also been shown to be involved in the regulation of apoptosis, a critical cellular process that plays a role in disease development and progression. Its interaction with

Protein Name: AT-rich Interaction Domain 4A

Functions: DNA-binding protein which modulates activity of several transcription factors including RB1 (retinoblastoma-associated protein) and AR (androgen receptor) (By similarity). May function as part of an mSin3A repressor complex (PubMed:14581478). Has no intrinsic transcriptional activity (By similarity). Plays a role in the regulation of epigenetic modifications at the PWS/AS imprinting center near the SNRPN promoter, where it might function as part of a complex with RB1 and ARID4B (By similarity). Involved in spermatogenesis, together with ARID4B, where it acts as a transcriptional coactivator for AR and enhances expression of genes required for sperm maturation. Regulates expression of the tight junction protein CLDN3 in the testis, which is important for integrity of the blood-testis barrier (By similarity). Plays a role in myeloid homeostasis where it regulates the histone methylation state of bone marrow cells and expression of various genes involved in hematopoiesis. May function as a leukemia suppressor (By similarity)

The "ARID4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARID4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets